See our Compliance Policy
Their stability, purity, handling, and storage conditions can all affect the integrity of the final product
Understanding the differences between injectable and oral peptide formats and the distinction between research and pharmaceutical grade peptides further informs your sourcing decisions
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
No, lipotropic injections are not available on the NHS as they are not recognised as evidence-based treatments and lack support from NICE guidance for weight management
Storage Instructions Correct storage is what preserves the peptides stability and activity
